Last reviewed · How we verify
Topic Morphine
Topic Morphine, marketed by Hospital General de Niños Pedro de Elizalde, holds a position in the pain management market with a key composition patent expiring in 2028. The drug's competitive advantage lies in its established market presence and mechanism of action, though specific details on its primary indication and revenue are not provided. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Topic Morphine |
|---|---|
| Also known as | Morphine gel |
| Sponsor | Hospital General de Niños Pedro de Elizalde |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Regional Nerve Blocks to Improve Analgesia and Recovery in Older Adults Undergoing Spinal Fusion (EARLY_PHASE1)
- Next Generation Personalized Neuroblastoma Therapy (PHASE1)
- Effects of an Opioid Free/Sparing Care Pathway for Patients Undergoing Obesity Surgery (NA)
- Effectivness of Tramadol or Topic Lidocaine on Postoperative Analgesia in Laparoscopic Colorectal Resection. (NA)
- Randomized, Double-blind, Placebo, Controlled Cross Over Design Topical Morphine for Analgesia in Pediatric Procedures (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |